Literature DB >> 29202666

DBCG hypo trial validation of radiotherapy parameters from a national data bank versus manual reporting.

Carsten Brink1,2, Ebbe L Lorenzen2, Simon Long Krogh2, Jonas Westberg2, Martin Berg3, Ingelise Jensen4, Mette Skovhus Thomsen5, Esben Svitzer Yates5, Birgitte Vrou Offersen6,7.   

Abstract

INTRODUCTION: The current study evaluates the data quality achievable using a national data bank for reporting radiotherapy parameters relative to the classical manual reporting method of selected parameters.
METHODS: The data comparison is based on 1522 Danish patients of the DBCG hypo trial with data stored in the Danish national radiotherapy data bank. In line with standard DBCG trial practice selected parameters were also reported manually to the DBCG database. Categorical variables are compared using contingency tables, and comparison of continuous parameters is presented in scatter plots.
RESULTS: For categorical variables 25 differences between the data bank and manual values were located. Of these 23 were related to mistakes in the manual reported value whilst the remaining two were a wrong classification in the data bank. The wrong classification in the data bank was related to lack of dose information, since the two patients had been treated with an electron boost based on a manual calculation, thus data was not exported to the data bank, and this was not detected prior to comparison with the manual data. For a few database fields in the manual data an ambiguity of the parameter definition of the specific field is seen in the data. This was not the case for the data bank, which extract all data consistently.
CONCLUSIONS: In terms of data quality the data bank is superior to manually reported values. However, there is a need to allocate resources for checking the validity of the available data as well as ensuring that all relevant data is present. The data bank contains more detailed information, and thus facilitates research related to the actual dose distribution in the patients.

Entities:  

Mesh:

Year:  2017        PMID: 29202666     DOI: 10.1080/0284186X.2017.1406140

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  5 in total

1.  Co-registration of radiotherapy planning and recurrence scans with different imaging modalities in head and neck cancer.

Authors:  Morten Horsholt Kristensen; Christian Rønn Hansen; Ruta Zukauskaite; Jørgen Johansen; Eva Samsøe; Christian Maare; Anne Ivalu Sander Holm; Jesper Grau Eriksen
Journal:  Phys Imaging Radiat Oncol       Date:  2022-06-30

2.  Prospectively scored pulmonary toxicities in non-small cell lung cancer: Results from a randomized phase II dose escalation trial.

Authors:  Christina M Lutz; Marianne M Knap; Lone Hoffmann; Ditte S Møller; Olfred Hansen; Carsten Brink; Tine Schytte; Christa H Nyhus; Tine McCulloch; Svetlana Borissova; Markus Alber; Azza A Khalil
Journal:  Clin Transl Radiat Oncol       Date:  2020-11-26

3.  Transparency in quality of radiotherapy for breast cancer in the Netherlands: a national registration of radiotherapy-parameters.

Authors:  Nansi Maliko; Marcel R Stam; Liesbeth J Boersma; Marie-Jeanne T F D Vrancken Peeters; Michel W J M Wouters; Eline KleinJan; Maurice Mulder; Marion Essers; Coen W Hurkmans; Nina Bijker
Journal:  Radiat Oncol       Date:  2022-04-12       Impact factor: 3.481

4.  Factors influencing harmonized health data collection, sharing and linkage in Denmark and Switzerland: A systematic review.

Authors:  Lester Darryl Geneviève; Andrea Martani; Maria Christina Mallet; Tenzin Wangmo; Bernice Simone Elger
Journal:  PLoS One       Date:  2019-12-12       Impact factor: 3.240

5.  Dose constraints for whole breast radiation therapy based on the quality assessment of treatment plans in the randomised Danish breast cancer group (DBCG) HYPO trial.

Authors:  M S Thomsen; M Berg; S Zimmermann; C M Lutz; S Makocki; I Jensen; M H B Hjelstuen; S Pensold; M P Hasler; M-B Jensen; B V Offersen
Journal:  Clin Transl Radiat Oncol       Date:  2021-04-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.